Shigeyuki Nada
University of Tokyo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shigeyuki Nada.
Journal of Biological Chemistry | 2003
Shigeyuki Nada; Takaki Shima; Hiroyuki Yanai; Holger Husi; Seth Garran Niels Grant; Masato Okada; Tetsu Akiyama
In order to study the role of tyrosine kinase signaling in the post-synaptic density (PSD), tyrosine-phosphorylated proteins associated with the PSD-95/NMDA receptor complex were analyzed. The NMDA receptor complex from the mouse brain was successfully solubilized with deoxycholate and immunopurified with anti-PSD-95 or anti-phosphotyrosine antibody. Immunoblot analyses revealed that the predominantly tyrosine-phosphorylated proteins in the NMDA receptor complex are the NR2A/B subunits and a novel 120 kDa protein. Purification and microsequencing analysis showed that the 120 kDa protein is mouse PSD-93/Chapsyn-110. Recombinant PSD-93 was phosphorylated by Fyn in vitro, and Tyr-384 was identified as a major phosphorylation site. Tyrosine phosphorylation of PSD-93 was greatly reduced in brain tissue from Fyn-deficient mice compared with wild-type mice. Furthermore, an N-terminal palmitoylation signal of PSD-93 was found to be essential for its anchoring to the membrane, where Fyn is also localized. In COS7 cells, exogenously expressed PSD-93 was phosphorylated, dependent on its membrane localization. In addition, tyrosine-phosphorylated PSD-93 was able to bind to Csk, a negative regulator of Src family kinases, in vitro as well as in a brain lysate. These results suggest that PSD-93 serves as a membrane-anchored substrate of Fyn and plays a role in the regulation of Fyn-mediated modification of NMDA receptor function.
Journal of Biological Chemistry | 1997
Zen-ichiro Honda; Takeshi Suzuki; Naoto Hirose; Makoto Aihara; Takao Shimizu; Shigeyuki Nada; Masato Okada; Chisei Ra; Yutaka Morita; Koji Ito
As an attempt to analyze the roles of C-terminal Src kinase (Csk) in the high affinity IgE receptor (FcεRI)-mediated signaling, we overexpressed Csk, a membrane-targeted form of Csk (mCsk), and a kinase-defective, membrane-targeted form of Csk (mCsk(−)) in rat basophil leukemia (RBL) 2H3 cells. Specific activity of Lyn at the basal state was decreased in Csk-expressing cells, and further decreased in mCsk-expressing cells. In mCsk(−)-expressing cells, basal specific activity of Lyn was increased, thereby indicating that mCsk(−) functioned as a dominant negative molecule. The onset of FcεRI-mediated Lyn activation was delayed in Csk-expressing cells, and further delayed in mCsk-expressing cells. In mCsk(−)-expressing cells, Lyn activation was rapid and quite long lasting. These findings indicate (i) Csk negatively regulates rapid FcεRI/Lyn coupling, and (ii) Csk activity is potentially required for its termination. The onsets of the series of events including tyrosyl phosphorylation of Syk, mitogen-activated protein (MAP) kinase activation, elevation of intracellular calcium concentration ([Ca2+] i ), and histamine release were all stepwisely delayed in Csk-expressing cells and in mCsk-expressing cells. The durations of Syk phosphorylation and MAP kinase activation also closely correlated with those of Lyn activation, but [Ca2+] i elevation and histamine release followed different temporal patterns: the delayed responses in Csk-expressing cells and in mCsk-expressing cells led to sustained [Ca2+] i oscillation and histamine release, while the prompt responses in parent cells and mCsk(−)-expressing cells rapidly subsided. These findings provide further evidence that the initiations of the FcεRI-mediated signals are upstreamly regulated by Src family protein tyrosine kinases and revealed that their terminations are regulated by Lyn-dependent (Syk and MAP kinase) and -independent ([Ca2+] i elevation and histamine release) mechanisms.
Journal of Biological Chemistry | 1991
Masato Okada; Shigeyuki Nada; Yuji Yamanashi; Tadashi Yamamoto; Hachiro Nakagawa
Proceedings of the National Academy of Sciences of the United States of America | 1992
Hisataka Sabe; B Knudsen; Masato Okada; Shigeyuki Nada; Hachiro Nakagawa; Hidesaburo Hanafusa
Oncogene | 1994
Shigeyuki Nada; Masato Okada; Shinichi Aizawa; Hachiro Nakagawa
Journal of Experimental Medicine | 1995
J A Gross; M W Appleby; S Chien; Shigeyuki Nada; S H Bartelmez; Masato Okada; Shinichi Aizawa; R M Perlmutter
Oncogene | 1993
Alasdair MacAuley; Masato Okada; Shigeyuki Nada; Hachiro Nakagawa; Jonathan A. Cooper
The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017
Masahiro Nakai; Masato Okada; Shigeyuki Nada; Akira Ogawa; Ayaka Kitamura; Tomokazu Nakai; Atsushi Nakagawa; Eiki Yamashita; Ryo Yonehara; Keiichi I. Nakayama; Hirokazu Nakatsumi
The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017
Haruyuki Hasegawa; Masato Okada; Shigeyuki Nada
The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017
Mao Ito; Takeshi Inoue; Shigeyuki Nada; Tomohiro Kurosaki; Masato Okada